Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cancer

Using aspirin for six months or more reduces the risk of some gastrointestinal cancers, study finds

Long-term use of aspirin can reduce the risk of several major types of gastrointestinal cancer and some non-gastrointestinal cancers, a 10-year population-based study has found[1].

Researchers carried out a matched-cohort study of a territory-wide database from all public hospitals in Hong Kong. Patients with aspirin prescribed for at least six months between 2000 and 2004 were extracted and matched with non-users in a 1:2 ratio. The average duration of aspirin prescribed was 7.7 years and the median dose was 80mg.

Cancer occurred in 15.9% of the 618,884 subjects and lung cancer was the most common.

Long-term use of aspirin showed a 24% to 47% significant reduction of major cancers in the gastrointestinal tract, including colorectal (24%), liver (47%), oesophageal (47%), pancreatic (34%) and gastric (38%) cancer. For non-gastrointestinal cancers, long-term use of aspirin only showed a significant reduction for leukaemia, lung and prostate cancers.

“The findings demonstrate that the long-term use of aspirin can reduce the risk of developing many major cancers,” said Kelvin Tsoi, research associate professor at the Chinese University of Hong Kong and lead author of the study.

“What should be noted is the significance of the results for cancers within the digestive tract, where the reductions in cancer incidence were all very substantial, especially for liver and oesophageal cancer,” he added.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203844

Readers' comments (2)

  • It will be interesting to know how and why effect on gastrointestinal Cancer was the most significant, and the lowest Aspirin dose producing that cancer-protection impact.

    Unsuitable or offensive? Report this comment

  • HanaFayyad
    Read the abstract.............

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Popular Medicines

    Popular Medicines

    An illustrated history of some of the most popular branded medicines. Includes colourful historical adverts and details of the medicine's formula and intended purpose.

    £22.00Buy now
  • Lecture Notes in Pharmacy Practice

    Lecture Notes in Pharmacy Practice

    A comprehensive study guide which summarises the basic principles in pharmacy practice. Clear, bulleted information for quick reference.

    £43.00Buy now
  • MCQs in Pharmacy Practice

    MCQs in Pharmacy Practice

    A study aid with 800 MCQs. Assess your knowledge, analytical skills, and ability to apply this knowledge base in clinical practice.

    £25.00Buy now
  • Biological Therapeutics

    Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £33.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • aspirin tablets close up

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.